By Tony Fong

NEW YORK (GenomeWeb News) – Taking aim at an opportunity that has been estimated at more than $1 billion in the US alone, several firms are using next-generation sequencing and other genomic technologies to break into the diagnostics market for fetal aneuploidy and chromosomal aberrations.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.